FDA-PR2026-10-13

Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

Get recalls like this in a free plain-English brief every Sunday.Get alerts ↓

Product photos

Argatroban Injection 250 mg/2.5 mL (100 mg/mL) vial label

Argatroban Injection 250 mg/2.5 mL (100 mg/mL) vial label 2

Hazard

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terepht

Official notice

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-health-issues-voluntary-nationwide-recall-argatroban-injection-due-presence-particulate-matter

More Par Health recalls

FDA-PR2026-10-08
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter
FDA-PR2026-09-18
Par Pharmaceutical dexmedetomidine injection recalled for particulate matter contamination

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Pet owners
Drivers & vehicles
Food allergies